Last updated on February 2018

Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: NIDDM
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Patients with type 2 diabetes
  • Patients treated by metformin and/or sulfonylureas (or glinides) and/or acarbose and/or insulin,
  • HbA1C >= 7 %,
  • Patients who gave their written consent.

For the kinetic substudy:

  • Patients who have the typical features of diabetic dyslipidemia (triglycerides >= 1.50 g/l and/or HDL<0.50 g/l [women], 0.40 g/l [men])

Exclusion Criteria:

  • Treatment with thiazolidinediones or other Glucagon-like peptide-1(GLP1) agonist.
  • No treatment with a Dipeptidyl peptidase-4 (DPP4) inhibitor during the 3 previous months,
  • Renal or hepatic failure,
  • Contra-indication for proton-spectroscopy (pacemaker, implantable prosthesis,..),
  • Pregnancy.

For the kinetic substudy:

  • Patients on hypolipidemic agents

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.